Page 1 | Search Results | Blood | American Society of Hematology

1-20 of 97

Sort by

Sort Order Select

Journal Articles

Mitoxantrone Hydrochloride Liposome Combined with Polatuzumab Vedotin and Dexamethasone (MPD) Is Highly Effective and Well Tolerated As Bridging Therapy before Chimeric Antigen Receptor T-Cell Therapy for Relapsed/Refractory Diffuse Large B Cell Lymphoma

Xin-di Liu, Jia Cong, Lei Yang, Jing Yang, Liang Wang

Blood (2024) 144 (Supplement 1): 6475.

https://doi.org/10.1182/blood-2024-209754

Published: 2024

Journal Articles

Polatuzumab Vedotin-Based Regimens As Bridging Therapy before Chimeric Antigen Receptor T-Cell Therapy for Relapsed/Refractory Diffuse Large B Cell Lymphoma

Xin-di Liu, Jia Cong, Jing Yang, Liang Wang

Blood (2024) 144 (Supplement 1): 6545.

https://doi.org/10.1182/blood-2024-203066

Published: 2024

Journal Articles

Orelabrutinib with or without Anti-CD20 Monoclonal Antibodies Is Highly Effective and Well Tolerated As First-Line Therapy for Marginal Zone B Cell Lymphoma

Na Yao, Xin Li, Jing Yang, Jia Cong, Liang Wang

Blood (2024) 144 (Supplement 1): 6541.

https://doi.org/10.1182/blood-2024-203548

Published: 2024

Journal Articles

Rapid Step-up Dosing Schedule of Glofitamab Is Feasible for Relapsed/Refractory Diffuse Large B Cell Lymphoma Patients

Jing Yang, Liang Wang

Blood (2024) 144 (Supplement 1): 6540.

https://doi.org/10.1182/blood-2024-202904

Published: 2024

Journal Articles

Safety and Efficacy of Bicistronic CD19/CD22 CAR T Cell Therapy in Childhood B Cell Acute Lymphoblastic Leukemia

Blood (2024) 144 (Supplement 1): 681.

https://doi.org/10.1182/blood-2024-204200

Published: 2024

Journal Articles

Nemtabrutinib, a Noncovalent Reversible BTK Inhibitor in Relapsed or Refractory Follicular Lymphoma: Results from the Phase 2 Bellwave-003 Study

Wojciech Jurczak, Isabelle Fleury, Antonio Pinto, Sanne Lugthart, Omur Gokmen Sevindik, Iryna Kryachok, Elizabeth Phillips, Fei Li, Chan Y. Cheah, Jing Yang, Yan Xu, Siyang Leng, Fangfang Lv

Blood (2024) 144 (Supplement 1): 1634.

https://doi.org/10.1182/blood-2024-201578

Published: 2024

Journal Articles

Nemtabrutinib, a Noncovalent Reversible BTK Inhibitor in Relapsed or Refractory Marginal Zone Lymphoma: Results from the Phase 2 Bellwave-003 Study

Pier Luigi Zinzani, Juan Carlos Dupont, Alessandra Tucci, Jing Yang, Yan Xu, Siyang Leng, Muhit Ozcan

Blood (2024) 144 (Supplement 1): 3016.

https://doi.org/10.1182/blood-2024-201646

Published: 2024

Journal Articles

Clinical Features and Therapeutic Evaluation of Central Nervous System Involvement in Pediatric Anaplastic Large Cell Lymphoma

Blood (2023) 142 (Supplement 1): 1709.

https://doi.org/10.1182/blood-2023-188173

Published: 2023

Journal Articles

Efficacy and Safety of Modified BV-AVD-R Regimen in Chinese Children with Previously Untreated Intermediate- and High-Risk Classical Hodgkin's Lymphoma: An Open Label, Non-Randomized, Single-Arm, Phase 2 Study from Single Center

Li Ying, Nan Li, Shuang Huang, Ling Jin, Jing Yang, Chunju Zhou, Xiaoling Wang, Yanlong Duan

Blood (2023) 142 (Supplement 1): 6212.

https://doi.org/10.1182/blood-2023-184375

Published: 2023

Journal Articles

Prognostic Impact of Minimal Disseminated Disease (MDD) and Minimal Residual Disease (MRD) in Chinese Pediatric Patients with ALK-Positive Anaplastic Large Cell Lymphoma (ALCL)

Blood (2023) 142 (Supplement 1): 6088.

https://doi.org/10.1182/blood-2023-188415

Published: 2023

Journal Articles

Brentuximab Vedotin Combined with Chemotherapy in the Treatment of Pediatric Patients with R/R Hodgkin Lymphoma: Results of a Real World Setting Study

Li Ying, Nan Li, Chunju Zhou, Shuang Huang, Ling Jin, Jing Yang, Miaomiao Shao, Hao Sun, Xiaoling Wang, Yanlong Duan

Blood (2023) 142 (Supplement 1): 6209.

https://doi.org/10.1182/blood-2023-182590

Published: 2023

Journal Articles

Clinical Pathology Characteristics of 221 Pediatric Anaplastic Large Cell Lymphoma-3 Years Follow up and Experience from China Net Childhood Lymphoma(CNCL)

Blood (2023) 142 (Supplement 1): 4489.

https://doi.org/10.1182/blood-2023-188761

Published: 2023

Journal Articles

Efficacy and Safety Analysis of Combination Therapy Based on Liposomal Mitoxantrone (Lipo-MIT) in Relapsed/Refractory NK/T-Cell Lymphoma

Liang Wang, Jing Yang, Liqiang Wei

Blood (2023) 142 (Supplement 1): 6210.

https://doi.org/10.1182/blood-2023-182678

Published: 2023

Journal Articles

Niclosamide Inhibits the Growth of Acute Lymphoblastic Leukemia Cells By Increasing Intracellular ROS and Activation of p53-PUMA/NOXA

Junbin Huang, Jing Yang, Yun Chen, Zhizhuang Joe Zhao, Chun Chen

Blood (2022) 140 (Supplement 1): 5917.

https://doi.org/10.1182/blood-2022-168825

Published: 2022

Journal Articles

Combination of Thrombopoietin Receptor Agonist and Recombinant Human Thrombopoietin for Treating Cancer Therapy Induced Thrombopenia

Dong Yan, Jing Yang, Yunfei Gao, Peihua Zhang, Chan Zhang, Yurong Cheng, Xuyang Zhang, Cong Fan, Kai Wang, Siyu Zhu, Baogen Zhang, Fengyuan Liu, Yingying Tong, Lei Wu

Blood (2022) 140 (Supplement 1): 8420–8421.

https://doi.org/10.1182/blood-2022-164490

Published: 2022

Journal Articles

ALK Inhibitor Plus Vinblasitine for Refractory/Relapsed Pediatric ALK+ Anaplastic Large Cell Lymphoma: A Prospective, One-Arm, Open-Label Real-World Study

Wenqun Zhang, Shan Wang, Jing Yang, Bo Hu, Ying Liu, Ling Jing, Qing Zhu, Yang Liu, Qinlong Zheng, Chunju Zhou, Zifen Gao, Yonghong Zhang

Blood (2021) 138 (Supplement 1): 1406.

https://doi.org/10.1182/blood-2021-149402

Published: 2021

Journal Articles

Membrane skeleton modulates erythroid proteome remodeling and organelle clearance

Yijie Liu, Yang Mei, Xu Han, Farida V. Korobova, Miguel A. Prado, Jing Yang, Zhangli Peng, Joao A. Paulo, Steven P. Gygi, Daniel Finley, Peng Ji

Blood (2021) 137 (3): 398–409.

https://doi.org/10.1182/blood.2020006673

Published: 2021

Includes: Multimedia, Supplemental data

Journal Articles

IL-6 Deficiency Reverses Leukemic Transformation in an MDS Mouse Model

Yang Mei, PhD, Yijie Liu, PhD, Xu Han, PhD, Jing Yang, PhD, Peng Ji, MDPhD

Blood (2020) 136 (Supplement 1): 36.

https://doi.org/10.1182/blood-2020-137026

Published: 2020

Journal Articles

Early response observed in pediatric patients with relapsed/refractory Burkitt lymphoma treated with chimeric antigen receptor T cells

Wenqun Zhang, Jing Yang, Chunju Zhou, Bo Hu, Ling Jin, Biping Deng, Yang Liu, Shan Wang, Alex H. Chang, Juan Du, Zifen Gao, Yonghong Zhang

Blood (2020) 135 (26): 2425–2427.

https://doi.org/10.1182/blood.2019002008

Published: 2020

Includes: Supplemental data

Journal Articles

Early Response Observed in Pediatric Patients with Refractory/Relapsed B-Cell Non-Hodgkin Lymphoma Treated with Sequential Chimeric Antigen Receptor T Cells

Wenqun Zhang, MD, Bo Hu, MD, Ling Jing, MD, Jing Yang, MD, Shan Wang, MD, Yang Liu, MD, Juan Du, MD, Yaoliang Ren, MD, Yonghong Zhang, MD

Blood (2019) 134 (Supplement_1): 1945.

https://doi.org/10.1182/blood-2019-125753

Published: 2019

NARROW

Mitoxantrone Hydrochloride Liposome Combined with Polatuzumab Vedotin and Dexamethasone (MPD) Is Highly Effective and Well Tolerated As Bridging Therapy before Chimeric Antigen Receptor T-Cell Therapy for Relapsed/Refractory Diffuse Large B Cell Lymphoma

Polatuzumab Vedotin-Based Regimens As Bridging Therapy before Chimeric Antigen Receptor T-Cell Therapy for Relapsed/Refractory Diffuse Large B Cell Lymphoma

Orelabrutinib with or without Anti-CD20 Monoclonal Antibodies Is Highly Effective and Well Tolerated As First-Line Therapy for Marginal Zone B Cell Lymphoma

Rapid Step-up Dosing Schedule of Glofitamab Is Feasible for Relapsed/Refractory Diffuse Large B Cell Lymphoma Patients

Safety and Efficacy of Bicistronic CD19/CD22 CAR T Cell Therapy in Childhood B Cell Acute Lymphoblastic Leukemia

Nemtabrutinib, a Noncovalent Reversible BTK Inhibitor in Relapsed or Refractory Follicular Lymphoma: Results from the Phase 2 Bellwave-003 Study

Nemtabrutinib, a Noncovalent Reversible BTK Inhibitor in Relapsed or Refractory Marginal Zone Lymphoma: Results from the Phase 2 Bellwave-003 Study

Clinical Features and Therapeutic Evaluation of Central Nervous System Involvement in Pediatric Anaplastic Large Cell Lymphoma

Efficacy and Safety of Modified BV-AVD-R Regimen in Chinese Children with Previously Untreated Intermediate- and High-Risk Classical Hodgkin's Lymphoma: An Open Label, Non-Randomized, Single-Arm, Phase 2 Study from Single Center

Prognostic Impact of Minimal Disseminated Disease (MDD) and Minimal Residual Disease (MRD) in Chinese Pediatric Patients with ALK-Positive Anaplastic Large Cell Lymphoma (ALCL)

Brentuximab Vedotin Combined with Chemotherapy in the Treatment of Pediatric Patients with R/R Hodgkin Lymphoma: Results of a Real World Setting Study

Clinical Pathology Characteristics of 221 Pediatric Anaplastic Large Cell Lymphoma-3 Years Follow up and Experience from China Net Childhood Lymphoma(CNCL)

Efficacy and Safety Analysis of Combination Therapy Based on Liposomal Mitoxantrone (Lipo-MIT) in Relapsed/Refractory NK/T-Cell Lymphoma

Niclosamide Inhibits the Growth of Acute Lymphoblastic Leukemia Cells By Increasing Intracellular ROS and Activation of p53-PUMA/NOXA

Combination of Thrombopoietin Receptor Agonist and Recombinant Human Thrombopoietin for Treating Cancer Therapy Induced Thrombopenia

ALK Inhibitor Plus Vinblasitine for Refractory/Relapsed Pediatric ALK+ Anaplastic Large Cell Lymphoma: A Prospective, One-Arm, Open-Label Real-World Study

Membrane skeleton modulates erythroid proteome remodeling and organelle clearance

IL-6 Deficiency Reverses Leukemic Transformation in an MDS Mouse Model

Early response observed in pediatric patients with relapsed/refractory Burkitt lymphoma treated with chimeric antigen receptor T cells

Early Response Observed in Pediatric Patients with Refractory/Relapsed B-Cell Non-Hodgkin Lymphoma Treated with Sequential Chimeric Antigen Receptor T Cells

Email alerts

ASH Publications

American Society of Hematology

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only